NCT03193047View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

April 7, 2017

Primary Completion Date

January 29, 2018

Study Completion Date

February 19, 2018

Conditions
Hypercholesterolemia
Interventions
DRUG

bempedoic acid 180mg

Daily bempedoic acid 180mg tablet in addition to monthly PCSK9i (evolocumab) background therapy

OTHER

placebo

Daily matching placebo tablet in addition to monthly PCSK9i (evolocumab) background therapy

DRUG

evolocumab

Monthly PCSK9i (evolocumab) background therapy

Trial Locations (1)

40213

L-MARC Research Center, Louisville

Sponsors
All Listed Sponsors
lead

Esperion Therapeutics, Inc.

INDUSTRY